WS
VRDN icon

Wedbush Securities’s Viridian Therapeutics VRDN Stock Holding History

Wedbush Securities’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-667
Closed -$11K – 1022
2020
Q2 		$11K Buy
+667
New +$7.57K ﹤0.01% 951
2020
Q1 		– Sell
-5,880
Closed -$42K – 1016
2019
Q4 		$42K Buy
+5,880
New +$60.3K ﹤0.01% 969

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wedbush Securities's VRDN Position: Q3 2020 in Review

Wedbush Securities sold out of Viridian Therapeutics (VRDN) in Q3 2020, closing a stake of 667 shares — an estimated $11K sold.

Wedbush Securities first reported a position in VRDN in Q4 2019 and held it in 2 quarters. The position peaked at $42K in Q4 2019. 26 funds tracked by Wall St. Rank hold VRDN as of Q3 2020.

  • Wedbush Securities reported no remaining Viridian Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Wedbush Securities sold 667 Viridian Therapeutics shares in Q3 2020, an estimated $11K.
  • Wedbush Securities first reported a position in Viridian Therapeutics in Q4 2019 and held it in 2 quarters.
  • Wedbush Securities's Viridian Therapeutics position peaked at $42K in Q4 2019.
  • 26 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2020.

Based on Wedbush Securities's 13F filing for Q3 2020, filed 20 Oct 2020.